Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4936 to 4950 of 7689 results

  1. NICE encourages research into endovascular stentgrafting of popliteal aneurysms and may review this procedure on publication of further evidence.

    Recommendation ID IPG390/1 Question NICE encourages research into endovascular stentgrafting of popliteal aneurysms and may review this

    Research recommendation
    Published
    9 June 2015

  2. NICE encourages the company, NHS England and treatment centres to collect more evidence, particularly on the longer-term benefits and costs of eliglustat and enzyme replacement therapy for treating type 1 Gaucher disease.

    Recommendation ID HST5/1 Question NICE encourages the company, NHS England and treatment centres to collect more evidence, particularly

    Research recommendation
    Published
    12 October 2018

  3. NICE encourages the peer-reviewed publication of all further research for percutaneous balloon valvuloplasty for fetal critical aortic stenosis. Further research could be in the form of controlled trials, analysis of registry data or other observational studies. It should address patient selection, timing of the intervention and the natural history of the disease.

    Recommendation ID IPG613/1 Question NICE encourages the peer-reviewed publication of all further research for percutaneous balloon valvuloplasty

    Research recommendation
    Published
    10 December 2018

  4. NICE highlighted the importance of collecting further data within registries of patients receiving biological treatments for psoriatic arthritis to obtain information on long-term outcomes, including adverse events.

    Recommendation ID TA220/1 Question NICE highlighted the importance of collecting further data within registries of patients receiving biological

    Research recommendation
    Published
    9 June 2015

  5. NICE noted that the cost effectiveness of lenalidomide compared with standard care for people with low- or intermediate-1-risk MDS associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate, was sensitive to whether the patient access scheme would be realised in clinical practice. The Committee agreed that it would be critical to generate evidence to support the following: - The proportion of people who become eligible for the patient access scheme, that is, that they remain on treatment beyond 26 cycles. - The benefit of lenalidomide after 26 cycles, that is the associated overall survival and health related quality of life for those who remain on treatment beyond 26 cycles.

    Recommendation ID TA322/1 Question NICE noted that the cost effectiveness of lenalidomide compared with standard care for people with low-

    Research recommendation
    Published
    9 June 2015

  6. NICE proposes that a clinical trial is needed to establish the relative effectiveness of mannitol compared with hypertonic saline.

    Recommendation ID TA266/1 Question NICE proposes that a clinical trial is needed to establish the relative effectiveness of mannitol compared

    Research recommendation
    Published
    9 June 2015

  7. NICE recognised the importance of further clinical trials comparing the effectiveness of the tyrosine kinase inhibitors (afatinib, erlotinib and gefitinib) in EGFR mutation-positive locally advanced or metastatic NSCLC.

    Recommendation ID TA310/1 Question NICE recognised the importance of further clinical trials comparing the effectiveness of the tyrosine

    Research recommendation
    Published
    9 June 2015

  8. NICE recommended further research into the clinical effectiveness of BCM – Body Composition Monitor-guided fluid management in people with chronic kidney disease having dialysis. It noted that the ongoing BISTRO study will assess the effect of the device in people aged 18 years or over having haemodialysis. Further research should collect clinical-outcome data in the following populations:- adults (aged 18 years and over) having peritoneal dialysis- babies, children and young people (aged under 18 years) having haemodialysis- babies, children and young people (aged under 18 years) having peritoneal dialysis.

    Recommendation ID DG29/1 Question NICE recommended further research into the clinical effectiveness of BCM – Body Composition Monitor-guided

    Research recommendation
    Published
    12 October 2018

  9. NICE recommended further research to explore the impact of having experiences of patients having continuous infusion 5-FU and take into account the impact on quality of life. The potential consequences of introducing pharmacokinetic dose adjustment should also be explored.

    Recommendation ID DG16/4 Question NICE recommended further research to explore the impact of having experiences of patients having continuous

    Research recommendation
    Published
    9 June 2015

  10. NICE noted advice from clinical experts that there is variability between the faecal immunochemical tests. This may affect the number of positive and negative results reported by the tests when a single threshold is used. It recommended further research to investigate the variability between technologies and encouraged the companies to make sure that results can be standardised for use in a symptomatic population.

    Recommendation ID DG30/2 Question NICE noted advice from clinical experts that there is variability between the faecal immunochemical tests

    Research recommendation
    Published
    15 October 2018

  11. NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks, are collected for all people having treatment with simeprevir in the NHS.

    Recommendation ID TA333/1 Question NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks

    Research recommendation
    Published
    9 June 2015

  12. NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks, is collected for all people treated with sofosbuvir in the NHS.

    Recommendation ID TA330/1 Question NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks

    Research recommendation
    Published
    9 June 2015

  13. NICE recommended that data on the effect of BCM – Body Composition Monitor-guided monitoring on health-related quality of life is collected and published. Prospective within-patient studies, which record quality of life and symptoms before and after having BCM – Body Composition Monitor-guided fluid management should be considered.

    Recommendation ID DG29/2 Question NICE recommended that data on the effect of BCM – Body Composition Monitor-guided monitoring on health-related

    Research recommendation
    Published
    12 October 2018

  14. NICE recommended that further research should be designed to generate robust evidence of the clinical- and cost-effectiveness of Holoclar for treating both eyes in people with bilateral limbal stem cell deficiency after eye burns if they do not have enough tissue for a conjunctival limbal autograft. The study should recruit people with bilateral disease and evaluate the effectiveness of treatment in both eyes. Outcomes should include transplant success and assessments of health-related quality of life using a generic preference-based measure.

    Recommendation ID TA467/2 Question NICE recommended that further research should be designed to generate robust evidence of the clinical-

    Research recommendation
    Published
    15 October 2018

  15. NICE recommended that research should be carried out to determine the relationship between activity and prosthesis failure.

    Recommendation ID TA304/1 Question NICE recommended that research should be carried out to determine the relationship between activity

    Research recommendation
    Published
    9 June 2015